Cargando…
Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
Vulvovaginal candidiasis (VVC) is experienced by an estimated 75% of women at least once in their lifetime and is recurrent, defined as three or more infections per year (RVVC) in 5–9%. Candida albicans is the most common causative agent, but up to 19% of infections may be related to non-albicans sp...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921437/ https://www.ncbi.nlm.nih.gov/pubmed/36785761 http://dx.doi.org/10.2147/DDDT.S339349 |